Salvianolic acid F

Catalog No.E2540

Technical Data

Formula	C17H14O6
Molecular Weight	314.29	CAS No.	158732-59-3
Solubility (25°C)*	In vitro


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Biological Activity

Description	Salvianolic acid F acts as a KRAS inhibitor, with activity against KRAS G12D. It suppresses NF-kB, MMP-9, and NO production. In vitro studies show it reduces cancer cell proliferation, invasion, and migration while promoting apoptosis through the EP300/PI3K/AKT pathway. In vivo experiments demonstrate its inhibition of KRAS-dependent lung cancer cell growth via PI3K/AKT signaling. This compound has potential applications in studying multiple cancer types, particularly KRAS G12D-associated NSCLC and ovarian cancer.
In vivo	Salvianolic acid F (10-20 mg/kg, i.p., each day for 15 days) is effective in inhibiting KRAS-driven lung tumor growth by influencing the downstream PI3K/AKT pathway in A549 xenografts nude mice model. Salvianolic acid F (10-20 mg/kg, i.p., every 2 days for 40 days) inhibits lung tumor growth by influencing the downstream PI3K/AKT pathway in KrasG12D mice model.

Description

Salvianolic acid F acts as a KRAS inhibitor, with activity against KRAS G12D. It suppresses NF-kB, MMP-9, and NO production. In vitro studies show it reduces cancer cell proliferation, invasion, and migration while promoting apoptosis through the EP300/PI3K/AKT pathway. In vivo experiments demonstrate its inhibition of KRAS-dependent lung cancer cell growth via PI3K/AKT signaling. This compound has potential applications in studying multiple cancer types, particularly KRAS G12D-associated NSCLC and ovarian cancer.

In vivo

Salvianolic acid F (10-20 mg/kg, i.p., each day for 15 days) is effective in inhibiting KRAS-driven lung tumor growth by influencing the downstream PI3K/AKT pathway in A549 xenografts nude mice model. Salvianolic acid F (10-20 mg/kg, i.p., every 2 days for 40 days) inhibits lung tumor growth by influencing the downstream PI3K/AKT pathway in KrasG12D mice model.

Protocol (from reference)

References

https://pubmed.ncbi.nlm.nih.gov/37783131/
https://pubmed.ncbi.nlm.nih.gov/40237524/

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.